Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Adaptimmune Therapeutics plc ADAP

Healthcare Biotechnology
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. Its engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types. Its cell therapy candidates include TCR T-cells and TruC T-cells. Its product candidates include... see more

Recent & Breaking News (NDAQ:ADAP)

Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune's Phase 2 SPEARHEAD-1 Trial

GlobeNewswire May 19, 2021

First Preclinical Data from Adaptimmune's Mesothelin HiT Program at ASGCT Demonstrate Antigen-specific Tumor Cell Killing in vitro and Complete Tumor Regression in an Animal Model

GlobeNewswire May 11, 2021

Adaptimmune Reports First Quarter Financial Results and Business Update

GlobeNewswire May 6, 2021

Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT

GlobeNewswire April 27, 2021

Adaptimmune to Report Q1 2021 Financial Results and Business Update on Thursday, May 6, 2021

GlobeNewswire April 22, 2021

Adaptimmune Reports Fourth Quarter / Full Year 2020 Financial Results and Business Update

GlobeNewswire February 25, 2021

Adaptimmune to Report Fourth Quarter/ Full Year 2020 Financial Results and Business Updates on Thursday, February 25, 2021

GlobeNewswire February 11, 2021

Adaptimmune to Showcase Market Potential for SPEAR T-cell Portfolio and Pipeline with Multiple Cell Therapy Platforms During Virtual Investor Day

GlobeNewswire November 20, 2020

Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of Patients and Disease Control Rate of 94% Presented at CTOS

GlobeNewswire November 19, 2020

Adaptimmune to Host Virtual Investor Day on Friday, November 20th

GlobeNewswire November 12, 2020

Two Confirmed Responses and Five out of Six Patients with Initial Tumor Reductions from Early Dose Cohorts of SURPASS Trial, Presented at SITC

GlobeNewswire November 9, 2020

Adaptimmune Reports Q3 Financial Results and Business Update

GlobeNewswire November 5, 2020

Adaptimmune to Report Q3 Financial Results and Business Update on Thursday, November 5, 2020

GlobeNewswire October 22, 2020

Adaptimmune Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS Trial

GlobeNewswire October 15, 2020

Promising Data from Phase 1 Trial with ADP-A2AFP in Liver Cancer at the International Liver Congress Confirm Safety Profile and Demonstrate Potential Benefit for Patients

GlobeNewswire August 28, 2020

Adaptimmune Reports Q2 Financial Results and Business Update

GlobeNewswire August 6, 2020

Adaptimmune Granted Access to PRIority MEdicines (PRIME) Regulatory Support by the European Medicines Agency for ADP-A2M4 for the Treatment of Synovial Sarcoma

GlobeNewswire July 23, 2020

Adaptimmune to Report Q2 Financial Results and Business Update on Thursday, August 6, 2020

GlobeNewswire July 22, 2020

Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary Shares

GlobeNewswire June 4, 2020

Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares

GlobeNewswire June 1, 2020